MVision AI Appoints Antti Pirskanen as New Chief Financial Officer

Helsinki, Finland – June 14, 2024 – MVision AI, a pioneering company in the development of innovative AI solutions for radiation oncology is pleased to announce the appointment of Antti Pirskanen as its new Chief Financial Officer (CFO). Antti will assume his responsibilities immediately, bringing extensive expertise in financial management and strategic growth to the company.

Antti Pirskanen joins MVision AI from Newil & Bau, where he served as CFO. During his tenure, he successfully navigated challenging market conditions, leading capital raisings and various business development projects. Antti’s distinguished career also includes an important role at Vaaka Partners, Finland’s leading private equity firm, where he drove substantial investments and played a key role in portfolio management and growth strategies.

Antti holds a Master of Science in Economics from the Helsinki School of Economics, with a major in Finance. His robust background in private equity, buyout investments and financial analysis makes him an invaluable addition to the MVision AI team.

“We are excited to welcome Antti Pirskanen to MVision AI,” said Dharanipathy Rangaraj, CEO of MVision AI. “Antti’s extensive experience and proven track record in financial leadership will be crucial as we continue to expand and innovate in the AI healthcare industry. His strategic vision and operational expertise will drive our financial strategy forward, supporting our mission to revolutionize healthcare through advanced AI solutions.”

Antti Pirskanen expressed his enthusiasm about joining MVision AI: “I am looking forward to joining MVision AI at such a pivotal time in the company’s growth. I look forward to working with the talented team at MVision AI to build on the company’s successes and contribute to its future achievements.”

For more information about MVision AI and its innovative solutions, visit www.mvision.ai.

Media Contact:

Sakthy Edamaruku

Communication Specialist

MVision AI

info@mvision.ai

About MVision AI

MVision AI is your trusted partner in healthcare innovation! MVision AI is an innovative software service provider for radiotherapy treatment planning and Imaging. Our AI-powered automatic segmentation tool, Contour+, helps to standardize contouring and automate segmentation to streamline the radiotherapy treatment planning workflow. We are a team of experienced professionals committed to revolutionizing the cancer care industry through the application of cutting-edge AI technology. At MVision AI, we understand the challenges faced by healthcare providers in delivering accurate, timely, and efficient cancer care to patients. That’s why we are developing a suite of AI-powered solutions that can help streamline radiation therapy workflows, enable treatment quality and lead to standardization.

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

20.11.2024

MVision AI Ranked Among the Top 10 in Deloitte Technology Fast 50 Finland for 2024

Helsinki, Finland, 20 November 2024 – MVision AI, a leading innovator in AI-driven solutions for oncology, is proud to announce its recognition among the top ten companies in the Deloitte Technology Fast 50 Finland 2024 ranking. This prestigious award acknowledges MVision AI's rapid growth and its mission-driven advancements in making…

Press Releases

7.11.2024

Safe and Ethical AI in Radiation Oncology: Regulations and MVision’s Compliance

Technology is evolving, and the same applies to Radiation Oncology. New ways and new tools require new rules. Artificial intelligence (AI)  brings tremendous potential, so the world has to learn how to get the best of it, safely.  Al systems identified as high-risk have to comply with strict requirements, including…

Articles

24.10.2024

MVision AI Secures FDA 510(k) Clearance for Contour+ Advanced CT and MR Models

Helsinki, October 2024 – MVision AI, a leading innovator in AI-powered solutions for radiotherapy, is thrilled to announce that its auto-contouring solution Contour+ has received FDA 510(k) clearance for three new models: Bones CT, Brain MR, and Male Pelvis MR T2, and five updated models: Brain CT, Abdomen & Lung…

Press Releases